Skip to Content
Search Menu
cncpt-artikel_lb_atf

FDA Approves Lecanemab for Treatment of Early Alzheimer’s Disease

FDA has given full accelerated approval of lecanemab for treatment of early Alzheimer’s Disease.

Get access

If you are a doctor or other health professional, you can access the entire article by creating a profile on BestPractice Nordic.

Relateret indhold

Positive Clinical Effects in the Early Stages of Alzheimer’s Disease: A Focus on Disease-Modifying Therapies

/ BestPractice Nordic
Alzheimer'sEAN24
Anne Koivisto

The Risk of Alzheimer’s Disease Can Develop Over 10-20 Years Before the Cognitive Symptoms Appear

/ Anne Koivisto
Alzheimer'sNeurologipäivät24 Play the Video 02:35
Eino Solje

New Biomarkers Will Revolutionize Clinical Practice for Early Onset Alzheimer’s and Dementia

/ Eino Solje
Alzheimer'sNeurologipäivät24 Play the Video 1:25

Mechanistic Exploration and the Development of New Biomarkers for Alzheimer’s Disease – Focusing on the Brain ‘Garbage’ Clearance System

/ Janet Jianying Zhang / He-Ling Wang / Anne-Brita Knapskog / Geir Selbæk / Evandro Fei Fang
Alzheimer's
Kristian Steen Frederiksen

New Treatments for Early Alzheimer’s On The Way

/ Kristian Steen Frederiksen
Alzheimer'sEAN24 Play the Video 4:05
Kristian Steen Frederiksen

New Treatments for Alzheimer’s Disease with Anti-Amyloid Antibodies

/ Kristian Steen Frederiksen
Alzheimer'sEAN24 Play the Video 4:28
Michael Schöll

Blood-Based Biomarkers for Early Alzheimer’s Disease Diagnosis

/ Michael Schöll
Alzheimer'sEAN24 Play the Video 3:15
Sanna-Kaisa Herukka

Anti-Amyloid Antibodies in Alzheimer’s Disease: New Treatments on the Horizon

/ Sanna-Kaisa Herukka
Alzheimer'sEAN24 Play the Video 1:34
Ludmilla Morozova-Roche

The Role of Pro-Inflammatory S100A9 Protein in Amyloid-Neuroinflammatory Cascade in Neurodegenerative Diseases

/ Ludmilla Morozova-Roche
Alzheimer'sEAN24Parkinson's Play the Video 4:38
Back to top